liver | PharmaTimes

Boehringer Ingelheim’s survodutide shows promise in liver fibrosis treatment

John Pinching — Fri, 07 Jun 2024 12:19:55 +0000

Phase 2 trial reveals significant improvement in MASH patients

Resolution unveils data for liver disease treatment at EASL 2024

John Pinching — Wed, 05 Jun 2024 11:13:33 +0000

Extended phase 2 study highlights macrophage cell therapy’s efficacy

Silent plight

John Pinching — Fri, 03 May 2024 11:43:55 +0000

Why a new approach is needed for primary biliary cholangitis trials

CymaBay begins phase 3 liver disease study

John Pinching — Mon, 14 Aug 2023 12:10:00 +0000

IDEAL study aims to determine the impact of seladelpar on alkaline phosphatase levels

Gilead to reveal pivotal liver disease research

John Pinching — Wed, 14 Jun 2023 11:37:00 +0000

Gilead will present real-world data on its efforts to advance WHO’s aim of eliminating viral hepatitis

Novartis and Pfizer link to develop NASH combo therapy

Selina McKee — Mon, 29 Oct 2018 11:28:00 +0000

Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease.

Gilead presents promising data for NASH drug

Selina McKee — Wed, 25 Oct 2017 11:04:00 +0000

Gilead has presented promising Phase II results for its experimental NASH drug GS-0976, showing significant reductions in the build up of liver fat and a marker of fibrosis.

US fast track for Shire’s liver drug

Selina McKee — Mon, 01 Aug 2016 08:35:00 +0000

US regulators have placed Shire's SHP626 on a fast-track regulatory pathway in the hope of potentially accelerating access to the experimental liver disease drug.